Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

glyCoVdrugs

Financiado

Cerrado

Inverting α-glucosidase inhibitors as potential drugs for SARS-CoV-2

Viral infections are still a major challenge in medical therapy. The recent outbreak of SARS-CoV-2 has again shown the immense threat these pathogens pose. In contrast to the direct-acting antivirals approach (targeting viral prot... ver más

31/08/2024

ULEI

Presupuesto desconocido

Líder del proyecto

UNIVERSITEIT LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-08-31

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

ULEI

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Inhibicov Hit-to-Lead Development of potent broad-spectrum coronavirus... 150K€ Cerrado

PISARSCOV SEVERE ACUTE RESPIRATORY SYNDROME SARS DESIGN SYNTHESIS... 170K€ Cerrado

G1_G2_NAINHIBIT Design synthesis and evaluation of potential group 1 and gr... 228K€ Cerrado

SPOTLESS Screening of small molecules to fight SARS CoV 2 by combinin... 257K€ Cerrado

PID2020-120099RA-I00 NUEVAS TERAPIAS ANTIVIRALES: ESTRATEGIA DE MULTIPRESENTACION... 92K€ Cerrado

DESCUBRIMIENTO DE NUEVOS INHIBIDORES DE LA PR... DESCUBRIMIENTO DE NUEVOS INHIBIDORES DE LA PROTEINA ACE2 PAR... 2M€ Cerrado

Duración del proyecto: 23 meses Fecha Inicio: 2022-09-01
Fecha Fin: 2024-08-31

Líder del proyecto

UNIVERSITEIT LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Viral infections are still a major challenge in medical therapy. The recent outbreak of SARS-CoV-2 has again shown the immense threat these pathogens pose. In contrast to the direct-acting antivirals approach (targeting viral proteases, polymerases or other viral enzymes involved in replication), which is mostly followed by the pharmaceutical industry, this proposal targeting host cell enzymes involved in the biogenesis of infectious virions. In this context inverting α-glucosidases are of special interest. They play an important role in cell functions, such as the correct folding of proteins in the endoplasmic reticulum (ER). However, up to now selective inverting α-glucosidase inhibitors are scarce, and chemical probes that report on these selectively in biological samples non-existent. The dedicated aim of this proposal is to overcome this absence of inhibitors and probes.To identify novel inhibitors, activity-based protein profiling (ABPP) will be applied. This powerful analytical method is a driving force in chemical biology and medicinal chemistry but depends heavily on the availability of mechanism-based enzyme inhibitors. Based on current knowledge on retaining α-glucosidase inhibitors, unprecedented inhibitors and probes for inverting α-glucosidases will be developed and applied to ABPP. Their synthesis follows a divergent synthesis method to efficiently produce a wide library of compounds, that will be screened on the target enzyme, human ER α-glucosidase I. As the work on retaining α-glycosidase has shown, inverting α-glucosidase inhibitors are likely to be important tools for advancing many areas of application that are outside the primary scope of the proposed research (antiviral agents). Overall, my proposal on inverting α-glycosidase inhibitors and probes will therefore make a significant contribution to the current state of the art in glycan research.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores